SOUTH SAN FRANCISCO, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call and slide webcast on Tuesday, December 9, 2014 at 10:30 AM Pacific Time to discuss the presentation of results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML), as well as an MD Anderson Cancer Center-sponsored Phase 1/2 study of vosaroxin and decitabine in newly diagnosed older patients with AML and high risk myelodysplastic syndrome, at the 56th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9 in San Francisco, California.
As recently announced, results from the VALOR trial will be presented in a late-breaking oral presentation at the ASH Meeting on Tuesday, December 9, 2014, at 8:45 AM in the Moscone Center, North Building, Hall D (abstract LBA-6). Results from the MD Anderson Cancer Center-sponsored study will be presented in an oral presentation on Monday, December 8, 2014, at 10:30 AM in the Moscone Center, South Building, Gateway Ballroom 103 (abstract 385).
The call can be accessed by dialing (866) 953-6858 (U.S. and Canada) or (617) 399-3482 (international), and entering passcode 63726372. To access the live audio webcast and slides, or the subsequent archived recording, visit the "Investors and Media – Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast and slides will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis' preliminary analysis, assessment and conclusions of the results of the VALOR trial, and the efficacy and commercial potential of vosaroxin. It is possible that such results or conclusions may change based on further analysis of the VALOR data. Words such as "will," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' preliminary analysis, assessment and conclusions of the results of the VALOR trial set forth in this release may change based on further analysis of such data and the risk that Sunesis' clinical studies for vosaroxin may not lead to regulatory approval. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2013, and Sunesis' other filings with the Securities and Exchange Commission, including Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Sunesis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
CONTACT: Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals, Inc. 650-266-3717
Source:Sunesis Pharmaceuticals, Inc.